Refine
Has Fulltext
- yes (5)
Is part of the Bibliography
- yes (5)
Document Type
- Journal article (4)
- Doctoral Thesis (1)
Keywords
- Angstsensitivität (1)
- Angststörung (1)
- CVID (1)
- Dmrt1bY (1)
- European Society for Immunodeficiencies (ESID) (1)
- German PID-NET registry (1)
- IgG substitution therapy (1)
- PID prevalence (1)
- Panikstörung (1)
- Selbstwirksamkeit (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (1)
- Kinderklinik und Poliklinik (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
- Medizinische Klinik und Poliklinik II (1)
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1-25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0-88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE-syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%-subcutaneous; 29%-intravenous; 1%-unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Background:
Sex determination relies on a hierarchically structured network of genes, and is one of the most plastic processes in evolution. The evolution of sex-determining genes within a network, by neo- or sub-functionalization, also requires the regulatory landscape to be rewired to accommodate these novel gene functions. We previously showed that in medaka fish, the regulatory landscape of the master male-determining gene dmrt1bY underwent a profound rearrangement, concomitantly with acquiring a dominant position within the sex-determining network. This rewiring was brought about by the exaptation of a transposable element (TE) called Izanagi, which is co-opted to act as a silencer to turn off the dmrt1bY gene after it performed its function in sex determination.
Results:
We now show that a second TE, Rex1, has been incorporated into Izanagi. The insertion of Rex1 brought in a preformed regulatory element for the transcription factor Sox5, which here functions in establishing the temporal and cell-type-specific expression pattern of dmrt1bY. Mutant analysis demonstrates the importance of Sox5 in the gonadal development of medaka, and possibly in mice, in a dmrt1bY-independent manner. Moreover, Sox5 medaka mutants have complete female-to-male sex reversal.
Conclusions:
Our work reveals an unexpected complexity in TE-mediated transcriptional rewiring, with the exaptation of a second TE into a network already rewired by a TE. We also show a dual role for Sox5 during sex determination: first, as an evolutionarily conserved regulator of germ-cell number in medaka, and second, by de novo regulation of dmrt1 transcriptional activity during primary sex determination due to exaptation of the Rex1 transposable element.
First‐line treatment of pediatric low‐grade glioma using surgery, radio‐ or chemotherapy fails in a relevant proportion of patients. We analyzed efficacy of subsequent surgical and nonsurgical therapies of the German cohort of the SIOP‐LGG 2004 study (2004‐2012, 1558 registered patients; median age at diagnosis 7.6 years, median observation time 9.2 years, overall survival 98%/96% at 5/10 years, 15% neurofibromatosis type 1 [NF1]). During follow‐up, 1078/1558 patients remained observed without (n = 217), with 1 (n = 707), 2 (n = 124) or 3 to 6 (n = 30) tumor volume reductions; 480/1558 had 1 (n = 332), 2 (n = 80), 3 or more (n = 68) nonsurgical treatment‐lines, accompanied by up to 4 tumor‐reductive surgeries in 215/480; 265/480 patients never underwent any neurosurgical tumor volume reduction (163/265 optic pathway glioma). Patients with progressing tumors after first‐line adjuvant treatment were at increased risk of suffering further progressions. Risk factors were young age (<1 year) at start of treatment, tumor dissemination or progression within 18 months after start of chemotherapy. Progression‐free survival rates declined with subsequent treatment‐lines, yet remaining higher for patients with NF1. In non‐NF1‐associated tumors, vinblastine monotherapy vs platinum‐based chemotherapy was noticeably less effective when used as second‐line treatment. Yet, for the entire cohort, results did not favor a certain sequence of specific treatment options. Rather, all can be aligned as a portfolio of choices which need careful balancing of risks and benefits. Future molecular data may predict long‐term tumor biology.
Fanconi anemia (FA) is a genetically heterogeneous disorder with 22 disease-causing genes reported to date. In some FA genes, monoallelic mutations have been found to be associated with breast cancer risk, while the risk associations of others remain unknown. The gene for FA type C, FANCC, has been proposed as a breast cancer susceptibility gene based on epidemiological and sequencing studies. We used the Oncoarray project to genotype two truncating FANCC variants (p.R185X and p.R548X) in 64,760 breast cancer cases and 49,793 controls of European descent. FANCC mutations were observed in 25 cases (14 with p.R185X, 11 with p.R548X) and 26 controls (18 with p.R185X, 8 with p.R548X). There was no evidence of an association with the risk of breast cancer, neither overall (odds ratio 0.77, 95%CI 0.44–1.33, p = 0.4) nor by histology, hormone receptor status, age or family history. We conclude that the breast cancer risk association of these two FANCC variants, if any, is much smaller than for BRCA1, BRCA2 or PALB2 mutations. If this applies to all truncating variants in FANCC it would suggest there are differences between FA genes in their roles on breast cancer risk and demonstrates the merit of large consortia for clarifying risk associations of rare variants.
In einer Studie mit 60 Patienten mit Panikstörung und einer aus 60 gesunden Probanden bestehenden Kontrollgruppe wurde eine standardisierte kognitive Verhaltenstherapie mit Psychoedukation und Expositionsübungen durchgeführt.
Zu verschiedenen Zeitpunkten wurde mittels Fragebögen die Angstsensitivität (ASI) und allgemeine Selbstwirksamkeitserwartung (GSE) gemessen. Weiterhin wurden Daten zu angstbezogenen Kognitionen (ACQ) und die Anzahl der Panikattacken pro Woche erhoben.
Patienten mit Panikstörung wiesen zu Beginn eine niedrigere allgemeine Selbstwirksamkeitserwartung und eine höhere Angstsensitivität auf als gesunde Probanden. Nach der Psychoedukation kam es zu einer Reduktion der Angstsensitivität, nach der Exposition zu einem Anstieg der Selbstwirksamkeitserwartung bei der Patientengruppe. Die Patientengruppe erreichte außerdem einen Rückgang der angstbezogenen Kognitionen. Die Anzahl der Panikattacken veränderte sich nicht signifikant.
Die Veränderung von mit der GSE-Skala gemessener Selbstwirksamkeitserwartung durch standardisierte kognitive Verhaltenstherapie bei Panikstörung wurde in der vorliegenden Studie erstmals beschrieben. Es wurde gezeigt, dass durch eine standardisierte kognitive Verhaltenstherapie bei Patienten mit Panikstörung neben einer Reduktion der Angstsensitivität nicht nur, wie bereits bekannt, die panikbezogene Selbstwirksamkeitserwartung gesteigert werden kann, sondern auch die allgemeine Selbstwirksamkeitserwartung.
Die Veränderungen wurden außerdem hinsichtlich des Angstsensitivitäts-Responderstatus untersucht. Patienten, die bezüglich der Angstsensitivität mehr als 50 % Verbesserung zeigten (ASI-Responder), zeigten nach der Therapie keinen signifikanten Unterschied mehr zu den Werten von Angstsensitivität, allgemeiner Selbstwirksamkeitserwartung und angstbezogenen Kognitionen der Kontrollgruppe. Bei den ASI-Respondern fanden der signifikante Anstieg des GSE-Werts und der Rückgang des ACQ-Werts bereits nach der Psychoedukation statt.
In zukünftigen Studien sollten Unterschiede zwischen ASI-Respondern und ASI-Non-Respondern sowie weitere Maßnahmen zur Reduktion von Angstsensitivität und zur Stärkung der Selbstwirksamkeitserwartung mit dem Ziel der Prävention und Therapie von Angsterkrankungen untersucht werden.